Drugs / Retlirafusp alfa
Trials 59 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT07581574 | May 2026 → May 2027 expected | gastroesophageal adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05198817 | Feb 2022 → Jan 2023 | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05048134 | Oct 2021 → Feb 2023 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded |
| Phase 1 | NCT04324814 | Mar 2020 → Feb 2023 | neoplasm | Atridia Pty Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04282070 | Mar 2020 → Apr 2022 | nasopharyngeal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03774979 | Jan 2019 → Mar 2023 | neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03710265 | Nov 2018 → Dec 2022 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT05896046 | Jun 2023 → Jun 2025 | Hodgkins lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT05503888 | Oct 2022 → Jul 2027 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05020925 | Sep 2021 → May 2022 | nasopharyngeal carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04856774 | Jun 2021 → Mar 2024 | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04679038 | Mar 2021 → Dec 2022 | cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04624217 | Nov 2020 → Sep 2021 | malignant pancreatic neoplasm | Jiangsu HengRui Medicine Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT04407741 | Sep 2020 → Dec 2024 | cancer, lymphoma | Chinese PLA General Hospital | Unknown | No outcome recorded |
| Phase 237 trials | ||||||
| Phase 2 | NCT07709767 | Aug 2026 → Dec 2028 expected | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07709533 | Jul 2026 → Jun 2029 expected | — | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07689851 | Jul 2026 → Jul 2028 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT07619911 | Jul 2026 → Jul 2028 expected | non-small cell lung carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07567326 | Jul 2026 → Dec 2028 expected | non-small cell lung carcinoma | Peking University Cancer Hospital & Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07682376 | Jun 2026 → May 2028 expected | esophageal squamous cell carcinoma | Harbin Medical University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07607210 | Jun 2026 overdue | gastroesophageal junction adenocarcinoma | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07618910 | May 2026 → May 2027 expected | esophageal squamous cell carcinoma | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07663071 | May 2026 → May 2028 expected | rectal cancer | Harbin Medical University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07550920 | May 2026 → Mar 2027 expected | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07610629 | May 2026 → Dec 2028 expected | gastric adenocarcinoma | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07464756 | Apr 2026 → May 2028 expected | gastric adenocarcinoma | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07517653 | Apr 2026 → Nov 2028 expected | melanoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07503639 | Apr 2026 → Apr 2028 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07524374 | Mar 2026 → Sep 2027 expected | esophageal squamous cell carcinoma | Zhigang Li | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07451795 | Mar 2026 → Mar 2028 expected | castration-resistant prostate carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07311408 | Jan 2026 → Jan 2028 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Jingdong Zhang | Recruiting | No outcome recorded |
| Phase 2 | NCT07355010 | Dec 2025 → Dec 2028 expected | ovarian cancer | Qinglei Gao | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07478731 | Dec 2025 → Dec 2027 expected | colorectal cancer | Hong Qiu | Recruiting | No outcome recorded |
| Phase 2 | NCT07175220 | Oct 2025 → Oct 2028 expected | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07102901 | Sep 2025 → Dec 2027 expected | gastric cancer, gastroesophageal junction adenocarcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07147088 | Sep 2025 → Sep 2027 expected | intrahepatic cholangiocarcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07294664 | Jun 2025 → Jul 2027 expected | gastric cancer | The First Affiliated Hospital of Zhengzhou University | Recruiting | No outcome recorded |
| Phase 2 | NCT06881017 | May 2025 → Aug 2029 expected | gastric cancer, gastroesophageal junction adenocarcinoma | China Medical University, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06679673 | Dec 2024 → Dec 2025 overdue | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05671822 | Mar 2023 → Dec 2027 expected | gastroesophageal adenocarcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05300269 | Jul 2022 → Jul 2024 overdue | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05106023 | Jan 2022 → Sep 2023 | melanoma | Yong Chen | Unknown | No outcome recorded |
| Phase 2 | NCT05177497 | Jan 2022 → Jul 2024 | non-small cell lung carcinoma | Shanghai Chest Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04974957 | Aug 2021 → Feb 2022 | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04937972 | Jul 2021 → Dec 2024 | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04884009 | May 2021 → Dec 2022 | lung cancer | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04650633 | May 2021 → Jan 2023 | head and neck squamous cell carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04699968 | Jan → Nov 2021 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04580498 | Nov 2020 → Jul 2023 | non-small cell lung carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04560244 | Sep 2020 → Sep 2022 | non-small cell lung carcinoma | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 2 | NCT04355858 | May 2020 → May 2023 | breast cancer, metastatic malignant neoplasm | Fudan University | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05149807 | Jan 2022 → Apr 2024 | gastroesophageal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Terminated | No outcome recorded |
| Phase 2/3 | NCT04856787 | Jun 2021 → Apr 2024 | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Terminated | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07677293 | Jun 2026 → Dec 2028 expected | adenocarcinoma | Peking University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05179239 | Feb 2022 → Aug 2024 | cervical cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT05132413 | Dec 2021 → Dec 2024 | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04950322 | Dec 2021 → May 2024 overdue | gastroesophageal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07493382 | Apr 2026 → Apr 2027 expected | gastroesophageal junction adenocarcinoma | Tianjin Medical University Cancer Institute and Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06893887 | May 2025 → Mar 2027 expected | hepatocellular carcinoma | Nanjing Tianyinshan Hospital | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07384234 Background | Jan 2026 → Dec 2028 expected | gastroesophageal adenocarcinoma | Ruijin Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 61 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Retlirafusp Alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07709767 ↗ |
| Known as | SHR-1701 | “A Phase II Study of Neoadjuvant Adebrelimab or Retlirafusp Alfa (SHR-1701) in Combination With Recaticimab and Chemotherapy for Resectable Non-small Cell Lung Cancer” NCT07567326 ↗50“SHR1701，30mg/kg, intravenous infusion, every 3 weeks, use for up to 2 years at most.” NCT06893887 ↗ “Retlirafusp alfa (SHR-1701)” NCT07581574 ↗ |
| Action | Inhibit | “Anti-PD-L1/TGFβ fusion protein” NCT04324814 ↗ |
| Modality | Protein / enzyme biologic | “SHR-1701 is a new bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of TGF-β receptor II.” PMID 36280870 ↗ Oct 2022 |
| Route | Intravenous | “Subjects will receive an intravenous infusion of SHR-1701 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.” NCT03710265 ↗ |
| Target | CD274 | “SHR-1701 is a new bifunctional fusion protein composed of a monoclonal antibody against PD-L1 fused with the extracellular domain of TGF-β receptor II.” PMID 36280870 ↗ Oct 2022 |